Privatlivspræferencer
Inderes bruger cookies for at give en bedre brugeroplevelse og en personlig service. Ved at give samtykke til brugen af cookies kan vi udvikle en endnu bedre service og vil kunne levere indhold, der er interessant for dig.
  • Forum
  • Aktiemarkeder
    • MarkederRealtidskurser, indekser og markedsudvikling
    • BørskalenderKommende resultater, noteringer og virksomhedsbegivenheder
    • UdbyttekalenderKommende og tidligere udbytter
  • Selskaber
    • SelskaberGennemse og filtrer den fulde liste over børsnoterede selskaber
    • OpdagInspiration til din næste investering
    • BørsnoteringerNye noteringer og kommende børsintroduktioner
    • Invitationer til generalforsamlingerDatoer for generalforsamlinger og aktionærinformation
  • Aktieanalyse
    • ResearchEkspertaktieanalyse og anbefalinger
    • ArtiklerNyheder, indsigter og markedskommentarer
    • inderesTVVideocenter for aktieanalyse, forskning og ekspertkommentarer
    • TransskriptionerFuldstændige udskrifter af resultatopkald og investormøder
    • AktieoversigtSammenlign nøgletal og udvikling på tværs af flere aktier
    • Earnings SeasonCompare EPS estimates to reported results
    • ShortsalgSe hvilke børsnoterede selskaber der har offentliggjorte korte positioner
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.

Nexam Chemical: Busy pipeline, soft quarter - ABG

NEXAMEksterne analyser20.10.2026, 06.55

Dette er en ekstern analyse og afspejler ikke nødvendigvis vores perspektiv eller værdier

Download analyse (PDF)
* Sales SEK 42m (-15% vs. ABGSCe), EBIT -6.6m (ABGSCe -2.6m)
* We lower total ‘27e-‘28e sales by 4%, see break-even in FY'27e
* Recycling +66% y-o-y, record trial activity and growing pipeline

Q3 results

Sales were lower than expected at SEK 42m (-9% y-o-y, -15% vs. ABGSCe) in a seasonally weak quarter with what management termed a cautious restart after the summer. The miss was largely due to Performance Chemicals (-20% y-o-y, -29% vs. ABGSCe). HT remains affected by the inventory adjustment at its largest customer, although management expects this to be completed by year-end, stating on the call that the customer’s ‘27 volumes will likely be above the current low level. Lightweight underperformed following large Q2 deliveries, while Masterbatch was in line with our estimates. Recycling continues to grow and was up 66% y-o-y to SEK 9.3m (~22% of sales). The gross margin rose to 49% (46%) on better mix and EBIT came in at SEK -6.6m (ABGSCe -2.6m).

Estimate changes

Q3 came in below our expectations, and we consequently lower ‘26e-‘28e sales by 5%/4%/4% and total '26e-'28e EBIT by SEK 11m. We expect the company to reach break-even in FY'27e.

Record activity, sales yet to follow

Commercial activity was at record levels during Q3, with 86 samples shipped (+50% q-o-q), 12 commercial-scale trials (normally ~5) and 164 Recycling projects in early phases. 25 projects are in scale-up, with lead times to serial production ranging from months to years, which makes the timing of growth hard to predict. Management keeps its ambition to double Recycling sales in '26 but calls it a big challenge. Longer-term, Nexam targets an annual group sales run-rate of SEK 300m, albeit with no timeframe given. Management sees ~1/3 of incremental sales dropping through to earnings on the current cost base. The share has returned -36% L3M (vs. peers -19%, OMXSALLS +4%) and is trading at 1.0x-0.9x ‘27e-‘28e EV/Sales vs. peers at 0.9x-0.6x.